علاج التهاب المريء بالفيروس المضخم للخلايا عندما لا يكون المرض خفيفاً

References

1. IV ganciclovir is the therapy of choice (AI) and can be switched to oral valganciclovir once the person can tolerate and absorb oral medications, extrapolated from randomized, clinical trial data showing non-inferiority of oral valganciclovir for treatment of CMV disease in people receiving a solid organ transplant (SOT) (AIII).
2. Oral valganciclovir can be used in patients with mild disease (AIII).
3. Ganciclovira 5 mg/kg IV every 12 hours (AI); may switch to valganciclovir 900 mg PO every 12 hours once the patient can absorb and tolerate PO therapy (AIII)
4. 21–42 days or until signs and symptoms have resolved (AIII)